May 05, 2020
Oramed Pharmaceuticals to Present at the 80th American Diabetes Association Scientific Session, to be Held Virtually This Year in June
Apr 07, 2020
Oramed Patent in Canada Allowed for Oral Delivery of Proteins
Apr 01, 2020
Oramed Pharmaceuticals Issues CEO Shareholder Letter Providing Business Update Amid COVID-19
Mar 19, 2020
Oramed Receives Positive Feedback From End-of-Phase 2 Oral Insulin CMC Meeting With FDA
Feb 27, 2020
Oramed Pharmaceuticals Inc. Prices Public Offering of Common Stock for Aggregate Proceeds of $21 Million
Feb 26, 2020
Oramed Reports Positive Results in the Final Cohort of Its Phase 2b Oral Insulin Trial
Feb 04, 2020
Oramed to Present at BIO CEO & Investor Conference
Jan 30, 2020
Oramed Appoints Dr. Julio Rosenstock to Its Scientific Advisory Board
Jan 28, 2020
Oramed Patent in Europe to be Granted for Oral Delivery of Proteins
Jan 23, 2020
Oramed Elects Dr. Alexander Fleming to Scientific Advisory Board
Jan 21, 2020
Oramed Appoints Dr. Jay Skyler to Scientific Advisory Board
Jan 09, 2020
Oramed Pharmaceuticals Issues Letter to Shareholders
Dec 05, 2019
Oramed Appoints Dr. Arie Mayer to Board of Directors
Dec 02, 2019
Oramed to Present a Scientific Poster at International Diabetes Federation Congress
Nov 21, 2019
Oramed Patent Granted in Japan for Protease Inhibitor, a Key Component of Platform Technology
Nov 19, 2019
Oramed Provides Highlights and Data From Its Phase IIb Oral Insulin Study Investor Event
Nov 14, 2019
Oramed Pharmaceuticals to Discuss Positive Phase IIb Data at Investor Event and Conference Call on Monday, November 18th
Nov 12, 2019
Oramed Announces Successful Phase IIb Study of Oral Insulin in Type 2 Diabetes
Sep 18, 2019
Oramed to Present at Ladenburg Thalmann 2019 Healthcare Conference
Sep 17, 2019
Oramed Announces Last Patient Treated in Pivotal Phase IIb Trial of Oral Insulin ORMD-0801